Search
ROG.VX: Bleak outlook for BIRCH FIR & POPLAR
- Amit Roy
- Sep 29, 2015
- 1 min read
Roche’s atezolizumab data appears uncompetitive in both 1st and 2nd line lung cancer
New data at the European Cancer Congress confirms our concerns that Roche’s anti PD-L1 immunotherapy may be uncompetitive in both 1st and 2nd line lung cancer...
댓글